Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01VBU
|
|||
| Former ID |
DNC001682
|
|||
| Drug Name |
ISIS 28466
|
|||
| Drug Type |
Antisense drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Company |
Isis Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Smad7 messenger RNA (Smad7 mRNA) | Target Info | . | [1] |
| KEGG Pathway | Endocytosis | |||
| TGF-beta signaling pathway | ||||
| Hippo signaling pathway | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Panther Pathway | TGF-beta signaling pathway | |||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | |||
| Signaling events mediated by HDAC Class I | ||||
| IFN-gamma pathway | ||||
| BMP receptor signaling | ||||
| ALK1 signaling events | ||||
| TGF-beta receptor signaling | ||||
| Reactome | SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | |||
| WikiPathways | TGF Beta Signaling Pathway | |||
| TGF beta Signaling Pathway | ||||
| Apoptosis-related network due to altered Notch3 in ovarian cancer | ||||
| Signaling by BMP | ||||
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | ||||
| Signaling by TGF-beta Receptor Complex | ||||
| Integrated Breast Cancer Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | US patent application no. 6,159,697, Antisense modulation of Smad7 expression. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.